Form 4: Inmune Bio CEO Raymond Tesi Acquires 160,000 Stock Options
SEC Form 4 Filing
Raymond Joseph Tesi, CEO of Inmune Bio, Inc., reports the acquisition of 160,000 stock options on May 14, 2024.
Summary
- Raymond Joseph Tesi, the President and CEO of Inmune Bio, Inc., filed a Form 4 on May 16, 2024.
- The report details a transaction that occurred on May 14, 2024, where Tesi acquired 160,000 options to purchase common stock.
- These options were granted pursuant to the 2021 Stock Incentive Plan with an exercise price of $9.92.
- The options vest over four years, with one-fourth vesting after the first year and the remainder vesting monthly over the subsequent three years.
- Following this transaction, Tesi directly owns 160,000 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The vesting schedule is typical for such grants.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.
- The vesting schedule of four years with a one-year cliff is a common structure to ensure long-term commitment.
Stakeholder Impact
- Shareholders may view the option grant as a positive incentive for the CEO.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of the transaction where Raymond Joseph Tesi acquired stock options. |
| 05/16/2024 | Date the Form 4 was signed by Raymond Joseph Tesi. |
| 05/13/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.